



**May 21, 2021**

**To**  
**Corporate Relations Department**  
**BSE Limited**

**Sub:** Decrease in shareholding of Vanta Bioscience Limited in Vayam Research Solutions Limited, Step down subsidiary

**Ref:** Disclosure under Reg 30 of SEBI (LODR), Regulation, 2015

Vayam Research Solutions Limited ("**Vayam**") is a step down subsidiary of Vanta Bioscience Limited ("**Company/Vanta Bio**"). The Company held 56.60% shareholding in Vayam through its wholly owned subsidiary Vanta Clinical Research Limited ("**VCRL**").

In order to meet its working capital requirements, Vayam has made an offer for issue of shares by means of Rights issue to all the existing shareholders of the Company. VCRL did not participate in the said offer and has renounced its rights under the said offer.

Accordingly, the Board of Vayam in their meeting held on 21.05.2021 has allotted shares in accordance with the said rights issue and thereby the shareholding of the VCRL/Company now stands reduced to 36.04%.

As the shareholding of Company/VCRL in Vayam is below 50% of the total equity share capital, Vayam ceases to be a subsidiary of VCRL and step down subsidiary of the Company w.e.f 21.05.2021.

In terms of SEBI CIR/CFD/CMF/4/2015 dated September 09, 2015, we hereby submit the following information in this connection:

The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year 2019-2020	Turnover Rs.1414.31Lakhs Other Income-Rs.10.98 Lakhs Networth 2445.90 Lakhs
---	---



# Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,  
 Rasoolpura, Secunderabad - 500 003, INDIA.  
 Tel : +91 40 6657 5454, 2790 3226  
 Fax : +91 40 2790 8708  
 Website : www.vantabio.com  
 Email : info@vantabio.com  
 CIN No. : U74999TG2016PLC109280

Date on which the agreement for sale has been entered into	-NA- The decrease in shareholding of the Company is due to allotment/increase in total capital of the Company.
The expected date of completion of sale/disposal	Pursuant to allotment in Vayam on 21.05.2021, the shareholding of the Company has reduced below 50%
Consideration received from such sale/disposal;	-NA- The decrease in shareholding of the Company is due to allotment/increase in total capital of the Company.
Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	-NA- The decrease in shareholding of the Company is due to allotment of shares to Mr. Dopesh Raja Mulakala (Promoter & MD of VantaBio) in his individual/personal capacity.
Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length"	No
Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	-NA-

In accordance with our intimation to BSE Ltd. dated 31.03.2021, the Trading Window for all designated persons as under Insider Trading Policy of the Company is closed from April 01, 2021 till 48 hours after the declaration of audited financial results of the Company for the half year and year ended March 31, 2021.

This is for your information and dissemination to general public.

**for Vanta Bioscience Limited**  
**(Scrip Code: 540729 | Scrip ID: VANTABIO)**

*(Handwritten Signature)*

**DOPESH RAJA MULAKALA**  
**MANAGING DIRECTOR DIN: 01176660**



**Research Center :**  
 K2-B, 11<sup>th</sup> Cross Street, SIPCOT Industrial Complex,  
 Gummidipoondi, Thiruvallur District, Tamilnadu - 601 201.  
 Tel : 044 6790 1600